Araim Pharmaceuticals announced that the Food and Drug Administration (FDA) has granted Fast Track status to ARA290 for the treatment of Sarcoidosis-associated Small Fiber Neuropathy (SFN).

ARA 290 is a first in class compound which activates the natural repair system of the body by activating the innate repair receptor thus turning off systemic inflammation and turning on repair.

RELATED: Neurologic Disorders Resource Center

Clinical trials have shown potent anti-inflammatory and tissue protective properties. ARA 290 demonstrated significant improvements in the symptoms of SFN along with improved functional capacity and improvements in sensory function and nerve fiber density.

The company has completed an exploratory trial and Phase 2a trials. Currently a Phase 2b dosing trial is ongoing. Ariam plans to initiate Phase 3 trials in the 4th quarter of 2015.

For more information visit